CAR T Cells in Solid Tumors and Metastasis: Paving the Way Forward

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2024 Sep 24

PMID 39316265

Authors

Camilla Sirini

Laura De Rossi

Marta Angiola Moresco

Monica Casucci

Affiliations

Soon will be listed here.

Abstract

CAR T cell therapy, hailed as a breakthrough in cancer treatment due to its remarkable outcomes in hematological malignancies, encounters significant hurdles when applied to solid tumors. While notable responses to CAR T cells remain sporadic in these patients, challenges persist due to issues such as on-target off-tumor toxicity, difficulties in their trafficking and infiltration into the tumor, and the presence of a hostile and immunosuppressive microenvironment. This review aims to explore recent endeavors aimed at overcoming these obstacles in CAR T cell therapy for solid tumors. Specifically, we will delve into promising strategies for enhancing tumor specificity through antigen targeting, addressing tumor heterogeneity, overcoming physical barriers, and counteracting the immune-suppressive microenvironment.

Citing Articles

Progress in personalized immunotherapy for patients with brain metastasis.

Patel L, Kolundzic N, Abedalthagafi M NPJ Precis Oncol. 2025; 9(1):31.

PMID: 39880875 PMC: 11779815. DOI: 10.1038/s41698-025-00812-0.

References

Haslauer T, Greil R, Zaborsky N, Geisberger R . CAR T-Cell Therapy in Hematological Malignancies. Int J Mol Sci. 2021; 22(16). PMC: 8396650. DOI: 10.3390/ijms22168996. View

Hou A, Chen L, Chen Y . Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov. 2021; 20(7):531-550. DOI: 10.1038/s41573-021-00189-2. View

Dirkx A, Oude Egbrink M, Kuijpers M, van der Niet S, Heijnen V, Bouma-Ter Steege J . Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003; 63(9):2322-9. View

Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

Turley S, Cremasco V, Astarita J . Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015; 15(11):669-82. DOI: 10.1038/nri3902. View

Posey Jr A, Schwab R, Boesteanu A, Steentoft C, Mandel U, Engels B . Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 2016; 44(6):1444-54. PMC: 5358667. DOI: 10.1016/j.immuni.2016.05.014. View

Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading J . Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017; 18(8):1009-1021. DOI: 10.1016/S1470-2045(17)30516-8. View

Flugel C, Majzner R, Krenciute G, Dotti G, Riddell S, Wagner D . Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2022; 20(1):49-62. PMC: 10278599. DOI: 10.1038/s41571-022-00704-3. View

Lamers C, Sleijfer S, Vulto A, Kruit W, Kliffen M, Debets R . Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006; 24(13):e20-2. DOI: 10.1200/JCO.2006.05.9964. View

10.

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

11.

Walker A, Majzner R, Zhang L, Wanhainen K, Long A, Nguyen S . Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. Mol Ther. 2017; 25(9):2189-2201. PMC: 5589087. DOI: 10.1016/j.ymthe.2017.06.008. View

12.

Patel U, Abernathy J, Savani B, Oluwole O, Sengsayadeth S, Dholaria B . CAR T cell therapy in solid tumors: A review of current clinical trials. EJHaem. 2022; 3(Suppl 1):24-31. PMC: 9175685. DOI: 10.1002/jha2.356. View

13.

Dianat-Moghadam H, Nedaeinia R, Keshavarz M, Azizi M, Kazemi M, Salehi R . Immunotherapies targeting tumor vasculature: challenges and opportunities. Front Immunol. 2023; 14:1226360. PMC: 10506263. DOI: 10.3389/fimmu.2023.1226360. View

14.

Harlin H, Meng Y, Peterson A, Zha Y, Tretiakova M, Slingluff C . Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009; 69(7):3077-85. PMC: 3886718. DOI: 10.1158/0008-5472.CAN-08-2281. View

15.

Foeng J, Comerford I, McColl S . Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022; 3(3):100543. PMC: 9040186. DOI: 10.1016/j.xcrm.2022.100543. View

16.

Barkal A, Brewer R, Markovic M, Kowarsky M, Barkal S, Zaro B . CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019; 572(7769):392-396. PMC: 6697206. DOI: 10.1038/s41586-019-1456-0. View

17.

Theruvath J, Menard M, Smith B, Linde M, Coles G, Dalton G . Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med. 2022; 28(2):333-344. PMC: 9098186. DOI: 10.1038/s41591-021-01625-x. View

18.

Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499. PMC: 5931375. DOI: 10.1038/nature22396. View

19.

Zhang X, Hu L, Yang Q, Qin W, Wang X, Xu C . CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer. Oncogene. 2021; 40(23):3959-3973. DOI: 10.1038/s41388-021-01827-0. View

20.

Caronni N, La Terza F, Vittoria F, Barbiera G, Mezzanzanica L, Cuzzola V . IL-1β macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023; 623(7986):415-422. DOI: 10.1038/s41586-023-06685-2. View